Anti-VEGF treatment strategies for wet AMD

Jaclyn L. Kovach, Stephen G. Schwartz, Harry W. Flynn, Ingrid U. Scott

Research output: Contribution to journalReview article

80 Scopus citations


Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

Original languageEnglish (US)
Article number786870
JournalJournal of Ophthalmology
StatePublished - Dec 1 2012


All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this